- Home
- SGMO vs BMEA Comparison
SGMO vs BMEA Comparison
Compare SGMO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- BMEA
- Stock Information
- Founded
- SGMO 1995
- BMEA 2017
- Country
- SGMO United States
- BMEA United States
- Employees
- SGMO N/A
- BMEA N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- SGMO Health Care
- BMEA Health Care
- Exchange
- SGMO Nasdaq
- BMEA Nasdaq
- Market Cap
- SGMO 122.8M
- BMEA 125.0M
- IPO Year
- SGMO 2000
- BMEA 2021
- Fundamental
- Price
- SGMO $0.68
- BMEA $2.15
- Analyst Decision
- SGMO Strong Buy
- BMEA Strong Buy
- Analyst Count
- SGMO 7
- BMEA 8
- Target Price
- SGMO $5.29
- BMEA $10.63
- AVG Volume (30 Days)
- SGMO 5.4M
- BMEA 658.3K
- Earning Date
- SGMO 11-11-2025
- BMEA 10-28-2025
- Dividend Yield
- SGMO N/A
- BMEA N/A
- EPS Growth
- SGMO N/A
- BMEA N/A
- EPS
- SGMO N/A
- BMEA N/A
- Revenue
- SGMO $81,706,000.00
- BMEA N/A
- Revenue This Year
- SGMO $28.47
- BMEA N/A
- Revenue Next Year
- SGMO N/A
- BMEA N/A
- P/E Ratio
- SGMO N/A
- BMEA N/A
- Revenue Growth
- SGMO 565.52
- BMEA N/A
- 52 Week Low
- SGMO $0.41
- BMEA $1.29
- 52 Week High
- SGMO $3.18
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- SGMO 66.82
- BMEA 61.18
- Support Level
- SGMO $0.65
- BMEA $1.98
- Resistance Level
- SGMO $0.73
- BMEA $2.18
- Average True Range (ATR)
- SGMO 0.06
- BMEA 0.12
- MACD
- SGMO 0.02
- BMEA 0.01
- Stochastic Oscillator
- SGMO 67.74
- BMEA 75.76
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.